<DOC>
	<DOCNO>NCT02851745</DOCNO>
	<brief_summary>The primary objective study evaluate effect linagliptin 5 mg daily versus correspond placebo LV systolic function ( measure midwall shorten analysis ) patient T2DM document baseline concentric LV geometry LV systolic dysfunction .</brief_summary>
	<brief_title>Effects Linagliptin Left Ventricular Myocardial DYsfunction Patients With Type 2 DiAbetes Mellitus Concentric Left Ventricular Geometry</brief_title>
	<detailed_description>Multicentre , randomize , double blind , parallel group comparison DPP-4 inhibitor , linagliptin 5 mg od , versus placebo ( 1:1 ) patient T2DM document baseline concentric LV geometry LV systolic dysfunction . The management glycemia leave Investigator 's judgment inform clinical guideline . The Investigator therefore allow undertake appropriate action , i.e . : - Adjust background antidiabetic treatment . - Prescribe additional antidiabetic medication accord labeling ( exclusion DPP-4 inhibitor GLP-1 receptor agonist ) . The enrollment period last 12 month . The patient follow 48 week randomization . After randomization patient control visit 2 week ( Visit 3 ) 3 month randomization ( Visit 4 , week 12 ) . At Visit 4 blood sample collect . Afterwards patient one control visit 24 week randomization ( Visit 5 ) final visit 48 week randomization ( Visit 6 ) echocardiogram ECG perform blood sample collect . Patients still study treatment time final visit ( Visit 6 ) post treatment safety follow ( clinical visit phone contact ) 30 day study treatment discontinuation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Men woman age equal 40 year screen . Patients history T2DM lasting least six month prior screen visit . HbA1c ≤ 8.0 % ( ≤ 64 mmol/mol ) screening . Evidence sinus rhythm screen ECG evaluation No clinical signs/symptoms cardiac disease evidence coronary artery disease basis clinical , electrocardiographic echocardiographic evaluation screening . Evidence baseline echocardiographic examination concentric leave ventricular geometry , define relative wall thickness ≥ 0.42 . Relative wall thickness calculate enddiastolic ratio 2* posterior wall thickness/LV diameter . Evidence baseline echocardiographic examination LV systolic dysfunction define Midwall shortening ( MFS ) ≤15 % Obtained informed consent Patients confirm indication incretin treatment Uncontrolled diabetes : HbA1c &gt; 8.0 % ( &gt; 64 mmol/mol ) Fasting Plasma Glucose &gt; 300 mg/dL measure screening visit . Glitazones within last three month Permanent atrial fibrillation Uncontrolled hypertension ( define systolic blood pressure &gt; 160 and/or diastolic blood pressure &gt; 90 ) Unstable dosage change type antihypertensive , lipid lower antidiabetic drug within 4 week screen visit . Severe chronic renal dysfunction ( define estimate glomerular filtration rate &lt; 30 ml/min/1.73 m2 ) . Previous current document history untreated ( use CPAP ) obstructive sleep apnea syndrome Rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis . Previous current document history malignant disease Pregnancy breast feeding Documented alcohol drug abuse Anticipated poor compliance Current participation clinical trial investigational product</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>